Scientists stunned by species' remarkable behavior after being moved from captivity to wild: 'This is pretty big news'
The axolotl — an often smiley-faced salamander known for its ability to regenerate limbs and organs — is showing new powers of adaptability, as individuals bred in captivity are surviving releases into the wild, according to a recent study.
The research has sparked optimism for protecting these unusual creatures that are critically endangered in their native habitat, NPR reported in early May.
Researchers tracked 18 axolotls that had been bred in captivity and released in artificial and restored natural wetlands in southern Mexico City in 2017 and 2018, per the news outlet. They found that animals in the study were hunting, eating, and avoiding predators. The axolotls weren't just surviving but thriving and gaining weight.
"This is pretty big news because when you have animals in captivity, they lose a lot of their behaviors," Alejandra Ramos, the study's lead researcher, told NPR. "Like, they don't know how to recognize a predator, they don't know how to catch prey, and so we were a bit nervous when we released them because we didn't know if they were going to be able to survive."
Axolotls — whose name is connected to Xolotl, the Aztec fire and lightning god — are sometimes called Mexican salamanders, water monsters, or water dogs. Native to lakes in the Mexico City area, they have caught the attention of animal lovers the world over for their distinctive colors and seemingly amiable expressions. They've even become popular pets.
Only about 50 to 1,000 axolotl adults live in the wild, though, according to the Natural History Museum in London. Their numbers have dropped significantly because of factors such as habitat loss and environmental change — sometimes connected to pollution and global temperature increases — as well as overfishing, collection by humans, and dangers from invasive species.
The discovery that captive-bred axolotls can be reintroduced to natural habitats offers hope that wild populations could be re-established. On top of this is the good news that the study's salamanders were able to survive in habitats created by and restored by humans — which bodes well for local preservation efforts.
"If axolotls could survive in man-made habitats, it could help scale back the damaging effects of habitat degradation and climate change," the NPR report summarized.
Saving axolotls could have specific benefits to people, as scientists are still working to understand the animals' cancer-resistant qualities and regenerative bodies. The hope is that studying their unique characteristics could lead to breakthroughs for human health.
Meanwhile, there is strong support for protecting axolotls for their own sake and as indicators of healthy, functioning habitats. There have even been programs to adopt axolotls to save them.
Should the government be paying people to hunt invasive species?
Definitely
Depends on the animal
No way
Just let people do it for free
Click your choice to see results and speak your mind.
In the NPR report, Ramos noted a special significance for the Mexican researchers. "They're part of our culture, they're part of our history. And that makes them really special to us," she said.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Washington Post
2 hours ago
- Washington Post
Dan David Prize names 9 historians as winners of 2025 award
JERUSALEM — The Dan David Prize will award nine historians, archaeologists and filmmakers from around the world with $300,000 for their research, the foundation announced Tuesday. The award winners are researching a vast array of topics, from the notebook of Isaac Newton's roommate to the history and culture of Ethiopian Jews. The academics recently received the prize during a ceremony in Italy.


Medscape
2 hours ago
- Medscape
Research Links Affluence to Higher Scarring Alopecia Risk
Patients with frontal fibrosing alopecia (FFA) were significantly more likely to come from low vulnerability zip codes than those with alopecia areata (AA) in a study that also suggested that race was not an independent predictor of FFA. METHODOLOGY: Researchers conducted a retrospective study of patients from 15 states treated at Johns Hopkins Hospital, Baltimore, between 2015 and 2024. They analyzed 147 patients with FFA and 429 patients with AA from 15 US states, with 84.2% from Maryland. Patients with FFA were older than those with AA (median age, 62 years vs 44 years; P < .001). White patients were most affected by FFA (51.7% vs 38.8% of Black patients), and Black patients were most affected by AA (51.5% vs 32.4% of White patients). < .001). White patients were most affected by FFA (51.7% vs 38.8% of Black patients), and Black patients were most affected by AA (51.5% vs 32.4% of White patients). Researchers matched patients' zip codes with the US Centers for Disease Control and Prevention Social Vulnerability Index (SVI) data and evaluated differences in the level of vulnerability between the two groups. TAKEAWAY: Race was not an independent predictor of FFA when controlling for socioeconomic status and age. A higher proportion of patients with FFA lived in low-vulnerability zip codes than those with AA (50.3% vs 34.03%; P < .001) < .001) Patients with FFA were significantly more likely to be from low vulnerability zip codes than patients with AA (odds ratio [OR], 1.786; P = .009). IN PRACTICE: 'Our study suggests that FFA patients are more likely to be from affluent zip codes as determined by their SVI when compared to AA patients,' the authors wrote. 'We believe, therefore, that historical emphasis on race in FFA may have been overstated due to the impact of race on socioeconomic status.' SOURCE: The study was led by Jiana Wyche, MHS, Department of Dermatology, Johns Hopkins School of Medicine, and was published online on May 16 in the Journal of the American Academy of Dermatology . LIMITATIONS: The study was conducted at a single institution with most patients from Maryland, which may limit generalizability. DISCLOSURES: The study did not receive any funding. One author reported serving as a consultant for Pfizer, Lilly, Myovant, and Galderma; being on the advisory board for Olaplex and CPSkin Health; receiving royalties as editor of the UpToDate, and receiving research support from Janssen.


Medscape
4 hours ago
- Medscape
Long-Acting Muscarinic Antagonists Aid Asthma Care in Kids
Long-acting muscarinic antagonists (LAMAs), as add-on therapy to inhaled corticosteroids, improved peak forced expiratory volume in 1 second (FEV1) and reduced exacerbations in children younger than 12 years with moderate-to-severe asthma. METHODOLOGY: Researchers conducted a meta-analysis to assess the efficacy and safety of LAMAs as add-on therapy to inhaled corticosteroids in children with moderate-to-severe asthma. They included four randomized controlled trials and two observational studies, comprising 1210 children (0.5-11 years), that evaluated tiotropium as LAMA of choice, with a median follow-up of 15 weeks. All participants received inhaled corticosteroids both before and after screening and randomization, with mean doses ranging from 228 μg to 480 μg of budesonide or an equivalent dose. The primary outcome was a change in FEV1. Other outcomes evaluated were peak FEV1, forced vital capacity (FVC), forced expiratory flow 25%-75% (FEF25%-75%), and asthma control assessed via interviewer-administered asthma control questionnaire (ACQ-IA) scores. TAKEAWAY: LAMAs at any dose significantly improved peak FEV1 (mean difference [MD], 86.16 mL; P < .01), with 5 μg tiotropium leading to a greater improvement (MD, 113.05 mL; P < .01). < .01), with 5 μg tiotropium leading to a greater improvement (MD, 113.05 mL; < .01). FEF25%-75% demonstrated significant improvements with LAMAs (MD, 0.2518 L; 95% CI, 0.1971-0.3064; P < .01), while peak FVC showed no significant change. < .01), while peak FVC showed no significant change. Treatment with LAMAs was associated with improved asthma control, as assessed by ACQ-IA scores (MD, -0.07; P < .01), and a reduced risk for exacerbations (risk ratio [RR], 0.75; P = .013). < .01), and a reduced risk for exacerbations (risk ratio [RR], 0.75; = .013). Treatment with LAMAs was associated with fewer adverse events than control (RR, 0.88; P = .021). No deaths were reported, and no adverse events led to treatment discontinuation in any of the included studies. IN PRACTICE: 'We found that LAMA as an add-on therapy to ICS [inhaled corticosteroids], with or without associated LABA [long-acting beta-agonists], is effective and safe for moderate and severe asthma in children aged 6-11, improving lung function parameters in spirometry and protecting against exacerbations,' the authors wrote. SOURCE: This study was led by Gabriel Bolner, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil. It was published online on May 5, 2025, in Paediatric Respiratory Reviews . LIMITATIONS: This study included only patients with moderate-to-severe asthma or persistent symptoms, limiting the understanding of potential benefits for children with better-controlled asthma. Additionally, only one study included children aged 5 years or younger, making this population underrepresented in the pooled analysis. DISCLOSURES: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. No conflicts of interest were mentioned.